Healio
At a Boston masterclass, the Harvard obesity doctor said GLP-1s should be treated as indefinite care, since weight returns when they stop.
Recap by typeshit. Full story at Healio.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
In an exclusive interview, the former NBA star describes the change in his life as night and day. Tap through for how he talks about it.
The FDA approved weekly insulin Awiqli for children 10 and up with type 2 diabetes, while Lilly's retatrutide data adds pressure before Novo's nine-month numbers.
Loading…